Tivozanib Completed Phase 3 Trials for Advanced Renal Cell Carcinoma Treatment

clinicaltrials.gov IdentifierTitleDrugs
NCT01076010An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib Versus Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)
NCT01030783A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma